IP Library › Granted Patent US 7,812,127
Granted Patent B2
US 7,812,127 · App. 12/215,512 · Granted Oct 12, 2010

Glycosylated human G-CSF

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,812,127
App. No.
12/215,512
Granted
Oct 12, 2010
Kind
B2
Abstract

The invention relates to G-CSF molecules having certain O-linked oligosaccharide structures.

Claims (57)

1. A composition comprising human G-CSF wherein the composition comprises two or more G-CSF molecules each being glycosylated with a different oligosaccharide structure wherein the oligosaccharide structures are selected from the group consisting of:

wherein Gal=Galactose,

NAcGal=N-Acetyl-Galactosamine,

NAcGlu=N-Acetyl-Glucosamine, and

SA=Sialic Acid.

2. The composition of claim 1 wherein the composition comprises three or more G-CSF molecules each being glycosylated with a different oligosaccharide structure selected from the group of claim 1 .

3. The composition of claim 1 wherein the composition comprises four or more G-CSF molecules each being glycosylated with a different oligosaccharide structure selected from the group of claim 1 .

4. The composition of claim 1 wherein the composition comprises five G-CSF molecules each being glycosylated with a different oligosaccharide structure selected from the group of claim 1 .

5. The composition of claim 1 wherein the G-CSF is isolated.

6. The composition of claim 1 wherein the G-CSF molecules are pegylated.

7. A composition comprising human G-CSF wherein the composition comprises a G-CSF molecule glycosylated with an oligosaccharide structure consisting of:

wherein Gal=Galactose,

NAcGal=N-Acetyl-Galactosamine,

NAcGlu=N-Acetyl-Glucosamine, and

SA=Sialic Acid.

8. The composition of claim 7 wherein the G-CSF is isolated.

9. The composition of claim 7 wherein the G-CSF molecule is glycosylated at threonine 133.

10. The composition of claim 7 wherein the composition is a pharmaceutical composition.

11. The composition of claim 7 wherein the G-CSF molecule is pegylated.

12. A composition comprising human G-CSF wherein the composition comprises a G-CSF molecule glycosylated with an oligosaccharide structure consisting of:

wherein Gal=Galactose,

NAcGal=N-Acetyl-Galactosamine,

NAcGlu=N-Acetyl-Glucosamine, and

SA=Sialic Acid.

13. The composition of claim 12 wherein the G-CSF is isolated.

14. The composition of claim 12 wherein the G-CSF molecule is glycosylated at threonine 133.

15. The composition of claim 12 wherein the composition is a pharmaceutical composition.

16. The composition of claim 12 wherein the G-CSF molecule is pegylated.

17. A composition comprising human G-CSF wherein the composition comprises a G-CSF molecule glycosylated with an oligosaccharide structure consisting of:

wherein Gal=Galactose,

NAcGal=N-Acetyl-Galactosamine,

NAcGlu=N-Acetyl-Glucosamine, and

SA=Sialic Acid.

18. The composition of claim 17 wherein the G-CSF is isolated.

19. The composition of claim 17 wherein the G-CSF molecule is glycosylated at threonine 133.

20. The composition of claim 17 wherein the composition is a pharmaceutical composition.

21. The composition of claim 17 wherein the G-CSF molecule is pegylated.

22. A composition comprising human G-CSF wherein the composition comprises a G-CSF molecule glycosylated with an oligosaccharide structure consisting of:

wherein

Gal=Galactose,

NAcGal=N-Acetyl-Galactosamine,

NAcGlu=N-Acetyl-Glucosamine, and

SA=Sialic Acid.

23. The composition of claim 22 wherein the G-CSF is isolated.

24. The composition of claim 22 wherein the G-CSF molecule is glycosylated at threonine 133.

25. The composition of claim 22 wherein the composition is a pharmaceutical composition.

26. The composition of claim 22 wherein the G-CSF molecule is pegylated.

27. A composition comprising human G-CSF wherein the composition comprises a G-CSF molecule glycosylated with an oligosaccharide structure consisting of:

Gal-NAcGal-

wherein Gal=Galactose,

NAcGal=N-Acetyl-Galactosamine,

NAcGlu=N-Acetyl-Glucosamine, and

SA=Sialic Acid.

28. The composition of claim 27 wherein the G-CSF is isolated.

29. The composition of claim 27 wherein the G-CSF molecule is glycosylated at threonine 133.

30. The composition of claim 27 wherein the composition is a pharmaceutical composition.

31. The composition of claim 27 wherein the G-CSF molecule is pegylated.

Assignments (3)
CHANGE OF NAME Recorded Jan 30, 2009
From: AVIGENICS, INC.
To: SYNAGEVA BIOPHARMA CORP.
Reel/Frame 022177/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2008
From: IVARIE, ROBERT D.; MORRIS, JULIE A.; LIU, GUODONG
To: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Reel/Frame 022047/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2008
From: HARVEY, ALEX J.; RAPP, JEFFREY C.
To: AVIGENICS, INC.
Reel/Frame 022058/0033 →